Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited disorder characterized by tumors of the enteropancreas, parathyroid and anterior pituitary. The MEN1 gene was recently cloned, and germline mutations of the gene have been demonstrated in cases of MEN 1. Here, we report a Japanese family with a germline mutation of the MEN1 gene. The proband (44 y.o., male) had primary hyperparathyroidism (PHP) and pancreatic carcinoid, and his older sister (50 y.o.) had a history of parathyroidectomy for primary hyperparathyrodism at the age of 40. Clinical examination revealed no evidence of PHPor other MEN1-related tumors in his son. Direct sequencing analysis revealed a heterozygous germline mutation (lOOldelC) at codon 297 in exon 6 of the MEN1 gene in the proband and his son. Loss of heterozygosity (LOH) was also found in the resected parathyroid tissue of the proband. The deletion of cytosine 1001 observed in this case induces a frame shift, which causes the appearance of a stop codon (TAG) at codon 367. This mutation appears to be associated with tumors of the endocrine tissues in the cases studied. (Internal Medicine 40: 499-505, 2001) 
Introduction
It is well recognized that primary hyperparathyroidism and malignancyconstitute the two main causes of hypercalcemia.
Primary hyperparathyroidism leads to increased secretion of parathyroid hormone (PTH) from the parathyroid glands; it originates most often from adenoma (-80%), less commonly from hyperplasia (-20%) and very rarely from parathyroid carcinoma (less than 1 %) (1) . Multiple chromosomal regions have been shown to be missing in parathyroid adenomas, probably reflecting the deletion of tumor suppressor genes (2) (3) (4) . These chromosomal loci include portions of chromosomes lp, 6q, 15q and llq. On chromosome ll, one parathyroid protooncogene, the PRAD1or cyclin Dl gene, was discovered at the breakpoint of an inversion at Ilql3 (5) . The inversion led to juxtaposition of the regulatory domain of the PTH gene and the DNAencoding cyclin Dl. As a consequence, the cyclin Dl gene could be overexpressed (6) . Cyclin Dl gene rearrangements have been documented in 5%of parathyroid adenomas.
The l lq deletion has been shown to be associated with an autosomal dominant disorder, multiple endocrine neoplasia type 1 (MEN1) (7) . MEN1 is characterized by tumors of multiple endocrine organs, including the parathyroids, gastrointestinal endocrine tissues and anterior pituitary. The penetration of parathyroid lesions is the highest and is revealed at an early stage of MEN1 (95% of patients are under 30 y.o.), mostly as biochemical hypercalcemia (8) . The MEN1 gene has been mapped to chromosome 1 Iql3 and was recently cloned by Chandrasekharappa et al (9) . This gene contains 10 exons and encodes a 610-amino-acid polypeptide. Although the physiological role of the protein remains under investigation, it has been speculated to suppress tumorigenesis. Recently various heterozygous germline mutations in the MEN1 gene have been identified in cases of MEN1 (10) (11) (12) (13) . Here, we report a family with MEN1 whoshowed a mutation of lOOldelC in the proband and his son.
For editorial comment, see p 461.
Case Report
A 44-year-old manwas admitted to Saitama Medical School Hospital, referred from another hospital for evaluation and treatment of hypercalcemia and hypergastrinemia. He had a history of duodenal ulcer and type 2 diabetes, which had been treated with an H2 receptor antagonist (famotidine) and a sulfonylurea Fromthe Fourth Department of Internal Medicine, Saitama Medical School, Saitama and *Growth Factor Division National Cancer Center Research Institute, (glibenclamide). During the follow-up period, he was revealed to have gall bladder (GB) stones and pancreatic tumor by abdominal sonography, with elevation of serum gastrin levels. Although he was operated on for the pancreatic tumor and GB stones, serum gastrin levels remained elevated and hypercalcemia was also noticed. The pathology of the pancreatic tumor was compatible with pancreatic carcinoid tumors (Fig. 1) . He was then referred to our department for further evaluation. Physical examination showedan operation scar at the center of the abdomen. He was 157.8 cmtall with a weight of79.2 kg. Blood pressure was 122/80 mmHg.The patient was alert and no focal neurological signs were observed. Biochemical examination showed an elevation of transaminases (AST 57 IU/Z, ALT89 IU//), compatible with the fatty liver observed by abdominal sonography. Serum Ca and alkaline phosphatase levels were elevated to 1 1.6 mg/dl and 325 (normal range: 96-284) IU//, respectively. He had an older sister whohad undergone surgery for hyperparathyroidism about 10 years previously at the age of40 (Fig. 2 ). Since the patient had a pancreatic tumor and hypergastrinemia, biochemical and endocrinological examinations were performed to confirm MEN1. His serum growth hormone (GH) varied from 0.4 to 26.6 ng/ml with normal values ofIGF-1 and IGFBP-3 ( Table 1 ). As shown in Table 2 , GHresponded unusually to GRH, L-dopa and TRH. Basal values of other anterior pituitary hormones were within the reference range (Table 1 ). Brain magnetic resonance imaging indicated neither pituitary microadenoma nor significant enlargement of pituitary tissue (Fig. 3) . Examination of Ca metabolism showed hypercalcemia and low normal phosphate (2.7 mg/dl; normal range: 2.4-4.4) with an elevated serum intact parathyroid hormone level (100 pg/ml; normal range: 10-65) and a normal value of PTH-related peptide (0.3 pmol//; normal range: <0.6 pmol//). Ultrasonography verified enlargement of only a single parathyroid gland. This was also con- (6) is shown by an arrow. The shaded symbol indicates no evidence of MEN1-associated tumors but the presence of the same genetic mutation as that found in the proband. GHresponses were assessed by administration of GRH(100 jig), Ldopa (500 mg) and TRH(500 |ig). GRH: growth hormone-releasing hormone, TRH: thyroid hormone-stimulating hormone-releasing hormone.
firmed by a 99m-technetium-2-methoxyisobutylisonitrile (99mTc-MIBI) scan (Fig. 4) and a 20 1-thallium-99m technetiumsubtraction scan (2oixi/99mTcsubtraction scan). Hewas then operated on for parathyroidectomy. Although preoperative localization studies revealed only a single enlarged parathyroid gland, three other mildly enlarged glands were identified and removed. Somefragments of a gland were auto-transplanted to the forearm. He has been treated for the diabetes mellitus and a duodenal ulcer with insulin self-injection (24 units/day) and an H+, K+-ATPase inhibitor (omeprazole), respectively. He has also been carefully monitored for serum GH,Ca and gastrin levels at outpatient clinics: his gastrin level decreased to 1 54 pg/ml immediately after parathyroidectomy but the values again increased to 170-242 pg/ml. Informed consent was obtained for genetic analysis of the family, and the proband and his two children (a son and a daughter) agreed to be examined. Osaka) and PCR buffer (Takara Shuzo Co.) (10) . The initial denaturation was performed for 1 min at 95°C and was followed by 30 cycles of denaturation at 95°C (1 min), annealing at 64-68°C (2 min) and extension at 72°C (1 min) (10 vyVk/w Results Germline mutation analysis PCR amplification and direct sequencing of genomic DNA extracted from the blood of the proband and his son showed a heterozygous germline deletion of cytosine at position bp 1001 in exon 6 of the MEN1 gene (Fig. 5) . The deletion of 1001C causes a frame shift, which would generate a premature termination codon (TAG) at position 367.
DNAsequencing
LOH study LOHwas examined in the enlarged hyperplastic parathyroid gland from the proband. Analysis of the tissue DNArevealed that the lOOl delC mutant allele was predominant ( (Fig. 6 ).
Discussion
The MEN1 gene has been identified on chromosome 11q13. It contains 10 exons and encodes a 610-amino-acid polypeptide (9) . Although the physiological role of the gene has been eagerly sought, its precise function is still uncertain; however, it has been speculated that it suppresses tumorigenesis (1 1). To date, more than 80%ofMEN1 families have been shown to be positive for the MEN1gene mutation; more than half of the mutations cause truncation of menin, which would result in loss of function. Menin is localized mainly in the nucleus, and Guru et al (12) identified two functionally independent nuclear localization signals at residues 479-^97 and 588-608 in the Cterminal quarter of menin by site-directed mutagenesis and immunocytochemical analysis. Furthermore, it was also shown that menin interacts with the API transcription factor JunD and represses JunD-activated transcription (16 5 ) and microsatellite polymorphism analysis (Fig. 6 ) were most compatible with the loss of heterozygosity (LOH) of the parathyroid tissues; therefore, the parathyroid hyperplasia should be associated with this MEN1 gene mutation. The deletion of cytosine 1001 observed in this case induces a frame shift, which produces a premature termination codon at position 367 in the MEN1 gene. Recently Sato et al (ll) clearly showed that a diversity of MEN1 gene mutations exist in Japanese MEN1 and MENl-related tumors; therefore that genetic analysis is indispensable for MEN1families. By the age of 40 years, most individuals carrying the genetic disorder of MEN1 become hypercalcemic. It has been shownthat chronic hypercalcemia of either parathyroid or nonparathyroid origin can elevate serum gastrin concentrations ( 1 7). Changes in serum Ca levels have also been demonstrated to alter serum gastrin levels and gastric acid secretion in MEN1 (18) . Parathyroidectomy of MEN1 patients resulted in a reduction of serum gastrin levels and gastric acid secretion even when gastrin-producing tumors were present ( 19) . Therefore, it has been suggested that the first treatment option should be parathyroidectomy in patients with Zollinger-Ellison syndrome and hyperparathyroidism. In the present case, successful parathyroidectomy lowered serum Ca levels (from 1 1.6 to 9.3 mg/ dl), which also led to reduced serum gastrin levels (from 310 to 120 pg/ml). Recently it is commonly accepted that autogenous grafting of parathyroid tissue to the forearm is beneficial in the management of parathyroid hyperplasia (20) . The high rate of recurrence in MEN1 patients does not argue against the use of such autogenous grafts (20) , since there is a significant advantage in being able to removethe enlarged tumor under local anesthesia. This autogenous graft has been shownto control serum Ca levels more efficiently in patients with MEN1 (21) .
Elevated serum levels of GHare not uncommonin patients with MEN1. It has been reported that GH-producing pituitary tumors account for approximately one-fourth of pituitary adenoma in MEN1; these usually develop as multicentric tumors (19) . There are also some reports showing that pancreatic or other tumors occasionally produce GRH, whichelevates serum GHlevels (22, 23) . In these cases, plasma GHwas either not suppressed or paradoxically increased by an oral glucose load or by TRHadministration. In the present patient, basal levels of serum GHvaried widely. Even using high resolution MRI, no pituitary lesions were identified (Fig. 3 ). An authentic GHstimulus of GRHdid not significantly modulate serum GHlevels. It might be possible that tumors producing GRHremained in the pancreas or duodenal wall, although circulating GRHlevels could not be measured in this case. The changes of plasma GHlevels are carefully monitored at outpatient clinics.
In conclusion, we identified a germline mutation of the MEN 1 gene in a Japanese MEN1 family; the proband and his son had a lOOldelC mutation. Genetic analysis is helpful for identifying individuals affected by this hereditary disease and for determining the best therapeutic approach.
